CJC-1295 No DAC Vial
← All CJC-1295 No DAC research
CJC-1295 No DAC (also known as Modified GRF (1 29) or "Mod GRF 1-29") is a synthetic 29-amino-acid analog of human growth hormone-releasing hormone (GHRH), derived from the native GHRH(1 29) sequence with four amino-acid substitutions (Ala2, Gln8, Ala15, Leu27) that confer resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4).
Research goals: Growth Hormone
Description
CJC-1295 No DAC (also known as Modified GRF (1–29) or “Mod GRF 1-29”) is a synthetic 29-amino-acid analog of human growth hormone-releasing hormone (GHRH), derived from the native GHRH(1–29) sequence with four amino-acid substitutions (Ala2, Gln8, Ala15, Leu27) that confer resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). The peer-reviewed clinical and pharmacology literature on CJC-1295 has been published in the Journal of Clinical Endocrinology & Metabolism, Growth Hormone & IGF Research, and the American Journal of Physiology — Endocrinology and Metabolism.
In a 2006 randomized, placebo-controlled, double-blind escalating-amount trial of CJC-1295 in healthy adults published in the Journal of Clinical Endocrinology & Metabolism, single subcutaneous amounts produced concentration-dependent increases of approximately 2- to 10-fold in mean GH concentrations and 1.5- to 3-fold in IGF-1 concentrations, with effects on the GH/IGF-1 axis lasting between 6 and 14 days [1].
Important Note on the Evidence Base
Important note on the evidence base: The peer-reviewed human clinical trials of CJC-1295 (Teichman 2006; Ionescu & Frohman 2006) studied the version of the molecule conjugated to a Drug Affinity Complex (DAC) maleimide group, which binds covalently to circulating serum albumin and extends the plasma half-life to approximately 6–8 days. The product supplied here is the no-DAC form, which has the identical 29-amino-acid peptide backbone and the identical receptor activity but lacks the albumin-binding maleimide. As a result, the no-DAC form has a substantially shorter plasma half-life (approximately 30 minutes) and produces pulsatile rather than sustained GH stimulation. The studies summarized below are presented with their original DAC/no-DAC designation noted explicitly.
Published Research on CJC-1295
The following peer-reviewed studies are summarized below. Full citations and direct links to each publication appear in the References section. All human studies described in this section were conducted in adult human participants and used the DAC-conjugated form of the molecule.
Phase 1/2 Escalating-amount Trial — Teichman et al., Journal of Clinical Endocrinology & Metabolism (2006)
Teichman and colleagues conducted two randomized, placebo-controlled, double-blind escalating-amount trials of CJC-1295 (DAC form) in healthy adult volunteers, with study durations of 28 and 49 days. The trials evaluated single administration and repeated administration pharmacokinetics, pharmacodynamics (GH and IGF-1 response), and safety across an escalating amount-range.
The investigators reported that CJC-1295 produced sustained, concentration-dependent increases in GH and IGF-1 levels
in healthy adults [1]. Mean GH increased approximately 2- to 10-fold and IGF-1 increased approximately 1.5- to 3-fold relative to placebo, with elevations of the GH/IGF-1 axis persisting between 6 and 14 days after a single subcutaneous injection. No serious adverse events were reported at any amount level.
Read the full study: Prolonged Stimulation of Growth Hormone and IGF-1 Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults (JCEM 2006).
Pulsatility During Continuous Stimulation — Ionescu & Frohman, Journal of Clinical Endocrinology & Metabolism (2006)
Ionescu and Frohman investigated whether the sustained GHRH-receptor stimulation produced by the DAC-conjugated form of CJC-1295 disrupts the natural pulsatile pattern of pituitary GH secretion. The study used frequent-sampling protocols (10-minute interval blood collection over extended periods) to characterize GH secretory dynamics in healthy adult volunteers receiving single subcutaneous amounts of CJC-1295.
The authors reported that pulsatile GH secretion was preserved during continuous CJC-1295 stimulation, with basal GH levels elevated approximately 7.5-fold while the natural pulsatile rhythm of secretion was maintained [2]. The finding distinguished CJC-1295’s pharmacodynamic profile from continuous recombinant-GH administration, which suppresses endogenous pituitary pulsatility.
Read the full study: Pulsatile Secretion of Growth Hormone Persists during Continuous Stimulation by CJC-1295 (JCEM 2006).
Serum Protein Profile Effects — Sackmann-Sala et al., Growth Hormone & IGF Research (2009)
Sackmann-Sala and colleagues used quantitative proteomic analysis to characterize the downstream effects of CJC-1295 administration on the serum protein profile in healthy adult subjects. Two-dimensional gel electrophoresis with mass-spectrometry identification was used to quantify changes in circulating proteins one week after CJC-1295 administration relative to baseline.
The investigators reported significant changes in multiple GH/IGF-1-axis-responsive serum proteins one week after CJC-1295 administration, including alterations in proteins associated with lipid metabolism, acute-phase response, and protease inhibition [3]. The pattern was consistent with sustained activation of the GH/IGF-1 axis, providing molecular-level confirmation of the pharmacodynamic effects established in the earlier clinical studies.
Read the full study: Activation of the GH/IGF-1 Axis by CJC-1295 Results in Serum Protein Profile Changes in Normal Adult Subjects (Growth Horm IGF Res 2009).
Growth Restoration in GHRH-Knockout Mice — Alba et al., American Journal of Physiology — Endocrinology and Metabolism (2006)
Alba and colleagues evaluated CJC-1295 in a GHRH-knockout mouse model in which native GHRH gene expression has been ablated, producing severe growth failure that is not normalized by twice-daily injections of standard short-acting GHRH analogs. Three groups of one-week-old GHRHKO mice received CJC-1295 (2 µg) at 24-, 48-, or 72-hour intervals over a 5-week treatment period.
The authors reported that once-daily administration of CJC-1295 normalized growth in GHRHKO mice over the treatment period, with restoration of body weight and skeletal growth comparable to wild-type littermates [4]. The data established proof-of-concept that prolonged GHRH-receptor stimulation by a long-acting analog could fully substitute for absent endogenous GHRH signaling.
Read the full study: Once-Daily Administration of CJC-1295 Normalizes Growth in the GHRH Knockout Mouse (AJP-Endo 2006).
About the Compound
CJC-1295 was developed by ConjuChem Biotechnologies in the early 2000s as part of a program targeting long-acting analogs of GHRH for therapeutic use. The compound is structurally based on native human GHRH(1–44), specifically the biologically active 1–29 N-terminal fragment (the same fragment that constitutes sermorelin), with four amino-acid substitutions designed to block the principal proteolytic cleavage sites recognized by DPP-4 and other serum peptidases. The substitutions extend the in vivo half-life of the underlying peptide from approximately 7 minutes (native GHRH) to approximately 30 minutes (Mod GRF 1-29 / CJC-1295 no DAC).
The “DAC” designation refers to a Drug Affinity Complex bioconjugation: a maleimidopropionic-acid lysine appendage attached to the C-terminus that reacts covalently with the free cysteine-34 residue of human serum albumin after subcutaneous administration. Once bound, the peptide circulates with albumin (which has a natural plasma half-life of approximately 21 days), extending the effective half-life of CJC-1295 with DAC to approximately 6–8 days. The product supplied here is the no-DAC form — the underlying peptide backbone without the maleimide modification. The receptor-binding pharmacology and downstream signaling are identical between the two forms; only the pharmacokinetic profile differs.
- CAS Number: 863288-34-0 (Modified GRF 1-29 / CJC-1295 no DAC)
- Molecular Formula: C152H252N44O42
- Molecular Weight: 3367.97 g/mol
- Synonyms: Modified GRF (1–29), Mod GRF 1-29, CJC-1295 No DAC
- Receptor target (in research literature): Growth hormone-releasing hormone (GHRH) receptor
- Plasma half-life (no DAC): Approximately 30 minutes (vs. 6–8 days for the DAC-conjugated form)
- Regulatory status (as of publication): Investigational. Not approved by the FDA, EMA, or any other regulatory authority for any indication.
Product Specifications
Omnix Peptides supplies CJC-1295 No DAC as a sterile, lyophilized (freeze-dried) powder in a sealed glass vial intended exclusively for in vitro laboratory research. Each production lot is independently characterized using high-performance liquid chromatography (HPLC) and liquid chromatography–mass spectrometry (LC–MS) protocols.
- Format: Lyophilized powder
- Available strengths: 5 mg per vial · 10 mg per vial
- Verified Purity: >99% (HPLC, LC–MS)
- Container: Sterile, sealed glass vial
- Documentation: Batch-specific Certificate of Analysis (COA) available
Storage, handling, intended-use, and regulatory information are provided in the corresponding tabs on this product page.
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
- Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. doi:10.1016/j.ghir.2009.03.001
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
Preparation and storage
Research-only handling information. CJC-1295 No DAC is sold strictly for in vitro laboratory research. The handling and storage guidance below reflects standard practice in published peptide research literature. CJC-1295 No DAC is not a drug, supplement, or food product, and is not for human consumption, veterinary use, or medical applications.
Format
- Form: Vial
- Available strengths: 5mg · 10mg
- Verified purity: >99% (HPLC, LC–MS)
- Documentation: Batch-specific Certificate of Analysis (COA) included
Reconstitution for Research Use
CJC-1295 No DAC is supplied as a sterile, lyophilized powder. Reconstitution with bacteriostatic water (BAC water) is the standard preparation step used in published research protocols. The volume of BAC water used determines the final concentration of the reconstituted solution.
Example (for a 5mg vial reconstituted in 2 mL of BAC water):
- Total peptide: 5mg
- BAC water added: 2 mL
- Resulting concentration: ~2.5 mg/mL
Recommended practice:
- Use sterile bacteriostatic water (0.9% benzyl alcohol) for reconstitution; this preserves the solution for multi-week handling in laboratory settings.
- Allow the lyophilized powder to reach room temperature before opening the vial.
- Inject the BAC water against the inside wall of the vial — do not aim the stream directly at the lyophilized cake.
- Gently swirl the vial until the powder is fully dissolved. Do not shake.
- Once reconstituted, store the vial under refrigeration at 4 °C (39 °F).
Storage & Handling
- Upon receipt: Keep peptides cold and away from light.
- Lyophilized (unreconstituted): Stable at room temperature for several weeks; refrigeration at 4 °C (39 °F) is acceptable for short-term storage (days to weeks).
- Long-term storage (months to years): Freeze the lyophilized vial at −80 °C (−112 °F). Freezing optimally preserves peptide stability for extended periods.
- Reconstituted solution: Refrigerate at 4 °C (39 °F). Avoid freeze/thaw cycles, which can degrade peptide structure.
- Light exposure: Minimize exposure to direct light during handling; light can accelerate peptide degradation.
- Heat exposure: Do not leave the vial at room temperature longer than necessary for handling.
Important Notice
All Omnix Peptides products are sold for laboratory, research, or analytical purposes only. They are not for human consumption, veterinary use, or medical applications. Researchers and laboratory professionals must follow all applicable institutional, local, state, and federal regulations governing the handling of research compounds.
Citations
Citations and reference data. Omnix Peptides supplies research-grade compounds for use by qualified laboratory professionals. The references below cite published preclinical research conducted in animal models and in vitro systems. They are not intended to represent clinical evidence in humans, and CJC-1295 No DAC has not been approved by the FDA, EMA, or any other regulatory authority for any indication.
Compound Reference Data
- Compound: CJC-1295 No DAC
- CAS Number: 863288-34-0 (Modified GRF 1-29 / CJC-1295 no DAC)
- Molecular Formula: C152H252N44O42
- Molecular Weight: 3367.97 g/mol
- Sequence: —
- Synonyms: Modified GRF (1–29), Mod GRF 1-29, CJC-1295 No DAC
Selected Published Studies
The following peer-reviewed studies were conducted using animal models or in vitro cell-culture systems. They are listed here as a reference for researchers investigating CJC-1295 No DAC. None of these studies should be interpreted as recommending CJC-1295 No DAC for human use, treatment, or any clinical purpose.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
- Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. doi:10.1016/j.ghir.2009.03.001
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
Evidence-Base Disclosure
The published evidence base for CJC-1295 No DAC consists predominantly of preclinical research — animal models (often rats or mice) and in vitro cell-culture experiments. Where Phase I or Phase II human trials exist, they are noted in the compound page summary. Researchers should interpret the cited literature within the experimental context of each individual study.
Frequently asked questions
Frequently asked questions about the CJC-1295 No DAC Vial. Questions on this page cover handling, storage, documentation, and ordering. CJC-1295 No DAC is sold for laboratory, research, or analytical purposes only — not for human consumption, veterinary use, or medical applications.
How is the CJC-1295 No DAC Vial prepared for laboratory research?
The CJC-1295 No DAC Vial is supplied as a sterile, lyophilized (freeze-dried) powder. The standard preparation step described in published peptide research literature is reconstitution with bacteriostatic water (BAC water). The volume of BAC water used determines the final concentration of the solution. See the Amount & Handling tab for a worked reconstitution example.
Why is CJC-1295 No DAC supplied as a lyophilized powder rather than a pre-mixed solution?
Lyophilization (freeze-drying) is the standard format for research-grade peptides because it maximizes long-term stability. A lyophilized vial stored cold and away from light remains stable for substantially longer than a pre-mixed solution. Reconstitution by the researcher also allows control over the final solution concentration.
Can the reconstituted CJC-1295 No DAC solution be frozen?
Freeze/thaw cycles can degrade peptide structure and should generally be avoided. Reconstituted CJC-1295 No DAC should be stored under refrigeration at 4 °C (39 °F) and used within the active research timeframe described in the Amount & Handling tab. For long-term storage, keep the vial lyophilized and freeze at −80 °C (−112 °F) until use.
Is CJC-1295 No DAC approved by the FDA?
No. CJC-1295 No DAC is not approved by the FDA, EMA, or any other regulatory authority for any indication. CJC-1295 No DAC is sold by Omnix Peptides strictly for laboratory, research, or analytical purposes. It is not for human consumption, veterinary use, or medical applications.
What is included with each CJC-1295 No DAC Vial?
Each order includes the sealed product container and a batch-specific Certificate of Analysis (COA) verifying identity and purity by HPLC and LC–MS. The full COA library for Omnix Peptides is available at /coa-lab-reports/.
What is a Certificate of Analysis (COA), and how do I read it?
A COA is a batch-specific lab report that documents the identity, purity, and quality control results for the production lot you receive. The COA lists the compound name, CAS number, lot number, analytical methods used (HPLC, LC–MS), and the measured purity percentage. Every Omnix order includes the COA for the lot shipped.
What is the CAS number for CJC-1295 No DAC?
The CAS number for CJC-1295 No DAC is 863288-34-0 (Modified GRF 1-29 / CJC-1295 no DAC). Researchers can use this identifier to locate published literature in PubMed and other scientific databases.
How does Omnix Peptides ship orders?
Orders ship from a US-based facility with tracked domestic shipping. Free shipping is offered on orders over $99. Lyophilized vials and capsules ship at ambient temperature; sprays ship insulated when seasonal conditions require it. Tracking information is provided by email after the order ships.
What if my product arrives damaged or the seal is broken?
Contact Omnix Peptides within 48 hours of delivery. Product damaged in transit or arriving with a compromised seal will be replaced at no cost. See the Shipping & Return Policy at /shipping-return-policy/ for full terms.
Where can I find published research on CJC-1295 No DAC?
Peer-reviewed studies relevant to CJC-1295 No DAC are listed in the Citations tab on this product page. The same studies can be located independently on PubMed using the CAS number (863288-34-0 (Modified GRF 1-29 / CJC-1295 no DAC)) or the compound name.
Customer reviews
Certificate of Analysis
Certificate of Analysis (COA) for this batch is available on request. Email orders@omnixpeptides.com with your order number to receive a copy. COAs include HPLC purity analysis performed by an independent third-party laboratory.
Reviews
There are no reviews yet.